ergic53 antibodies Search Results


N/A
Protein ERGIC-53, also known as ER-Golgi intermediate compartment 53 kDa protein or lectin mannose-binding 1, is a protein that in humans is encoded by the LMAN1 gene. It is mapped to 18q21.32. The protein encoded
  Buy from Supplier

93
Santa Cruz Biotechnology anti ergic 53
Anti Ergic 53, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ergic53+antibodies/ERGIC-53+Antibody/10__1523_slash_jneurosci__4723___08__2009-44-34-35
Average 93 stars, based on 1 article reviews
anti ergic 53 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Proteintech lman1
Lman1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ergic53+antibodies/ERGIC-53+Antibody/pmc05427065-157-32-35
Average 93 stars, based on 1 article reviews
lman1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

91
ProSci Incorporated ergic53
S-Acylation controls the lipid environment of spike See also <xref ref-type=Figure S4 . (A) Coarse-grained (CG) model of spike’s transmembrane (TM) helix + C-terminal region (residues 1,201-end in UniProt P0DTC2 ) in trimeric form, inserted into a DPPC-(yellow)-DLiPC-(red)-cholesterol-(green) membrane model. Left, starting conditions: random lipid positions and stretched cytoplasmic tail; center, representative end state of same view after 3.75 μs of CG MD simulation of the S-palmitoylated protein depicts phase separation and spike partitioning. Right, side view of the same model after 2 μs of atomistic MD simulation in the S-palmitoylated form in a POPC membrane. (B) Quantification of contacts at equilibrium between the full TM helix, the luminal half, or the cytosolic half, and each lipid phase. Results are means ± SD (n = 10). (C) Vero E6 expressing spike-HA WT surface labeled with biotin and processed for fractionation. Western blot (WB) of biotinylated proteins (Surface-Strp. Pull-down) precipitated from each fraction were compared to unbound fractions (intracellular-unbound). (D) Quantification of spike-HA (all forms) in each fraction relative to the total signal in all 6 fractions. Results are mean ± SD, n = 3. (E and F) High-throughput automated microscopy of Vero E6 expressing spike-HA (WT, or 10C-A mutant) for 24 h immunolabeled for HA and stained with Filipin. (E) Total levels of filipin staining within HA-positive cells (or per cell—mock sample) quantified per number of nuclei. The data were averaged for 49 frames over 8 wells per condition. Each dot represents one independent well, and results are mean ± SEM. Equivalent results were obtained for three independent assays. (G) Vero E6 infected with SARS-CoV-2 24 h, MOI ≈ 0.1 were incubated with beta-methylcyclodextrin (βMCD) or not (Ctrl) for 30 min. Cell extracts were fractionated as in (C). DRM marker Caveolin1 (Cav1)-positive control, transferrin receptor (TfR)-negative control. (H and I) Quantification of spike forms (H) and caveolin 1 (I) signals as in (C). Results are mean ± SD, n = 3. (J) Vero E6 transfected with indicated siRNA (siCtrl or siMixT pool), infected and fractionated as in (G). (K–M) Quantification of (K) and (L). Spike (all forms) and (M) ERGIC53 in each fraction as in (C). Results are mean ± SD, n = 3. All p values were obtained by two-way (except for E, one-way) ANOVA. " width="250" height="auto" />
Ergic53, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ergic53+antibodies/ERGIC53+Monoclonal+Antibody/pmc08486083-6-0-2
Average 91 stars, based on 1 article reviews
ergic53 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier

90
GeneTex antibody anti-ergic-53 (gtx63674)
S-Acylation controls the lipid environment of spike See also <xref ref-type=Figure S4 . (A) Coarse-grained (CG) model of spike’s transmembrane (TM) helix + C-terminal region (residues 1,201-end in UniProt P0DTC2 ) in trimeric form, inserted into a DPPC-(yellow)-DLiPC-(red)-cholesterol-(green) membrane model. Left, starting conditions: random lipid positions and stretched cytoplasmic tail; center, representative end state of same view after 3.75 μs of CG MD simulation of the S-palmitoylated protein depicts phase separation and spike partitioning. Right, side view of the same model after 2 μs of atomistic MD simulation in the S-palmitoylated form in a POPC membrane. (B) Quantification of contacts at equilibrium between the full TM helix, the luminal half, or the cytosolic half, and each lipid phase. Results are means ± SD (n = 10). (C) Vero E6 expressing spike-HA WT surface labeled with biotin and processed for fractionation. Western blot (WB) of biotinylated proteins (Surface-Strp. Pull-down) precipitated from each fraction were compared to unbound fractions (intracellular-unbound). (D) Quantification of spike-HA (all forms) in each fraction relative to the total signal in all 6 fractions. Results are mean ± SD, n = 3. (E and F) High-throughput automated microscopy of Vero E6 expressing spike-HA (WT, or 10C-A mutant) for 24 h immunolabeled for HA and stained with Filipin. (E) Total levels of filipin staining within HA-positive cells (or per cell—mock sample) quantified per number of nuclei. The data were averaged for 49 frames over 8 wells per condition. Each dot represents one independent well, and results are mean ± SEM. Equivalent results were obtained for three independent assays. (G) Vero E6 infected with SARS-CoV-2 24 h, MOI ≈ 0.1 were incubated with beta-methylcyclodextrin (βMCD) or not (Ctrl) for 30 min. Cell extracts were fractionated as in (C). DRM marker Caveolin1 (Cav1)-positive control, transferrin receptor (TfR)-negative control. (H and I) Quantification of spike forms (H) and caveolin 1 (I) signals as in (C). Results are mean ± SD, n = 3. (J) Vero E6 transfected with indicated siRNA (siCtrl or siMixT pool), infected and fractionated as in (G). (K–M) Quantification of (K) and (L). Spike (all forms) and (M) ERGIC53 in each fraction as in (C). Results are mean ± SD, n = 3. All p values were obtained by two-way (except for E, one-way) ANOVA. " width="250" height="auto" />
Antibody Anti Ergic 53 (Gtx63674), supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ergic53+antibodies/antibody+anti+ergic+53++gtx63674+/pm26147081-272-24-26
Average 90 stars, based on 1 article reviews
antibody anti-ergic-53 (gtx63674) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

N/A
Protein ERGIC 53 like Antibody FITC is a Rabbit Polyclonal antibody against Protein ERGIC 53 like conjugated to FITC
  Buy from Supplier

N/A
Rabbit polyclonal antibody against Protein ERGIC-53-like conjugated to Biotin Isotype Note: IgG Host Note: Rabbit Conjugation Note: Biotin Reactivity Note: Human Application Note: ELISA
  Buy from Supplier

N/A
Protein ERGIC 53 like Antibody is a Rabbit Polyclonal antibody against Protein ERGIC 53 like
  Buy from Supplier

N/A
Rabbit polyclonal antibody to Protein ERGIC-53-like Isotype Note: IgG Host Note: Rabbit Conjugation Note: Unconjugated Reactivity Note: Human Application Note: ELISA
  Buy from Supplier

N/A
Protein ERGIC 53 like Antibody HRP is a Rabbit Polyclonal antibody against Protein ERGIC 53 like conjugated to HRP
  Buy from Supplier

N/A
Rabbit polyclonal antibody against Protein ERGIC-53-like conjugated to FITC Isotype Note: IgG Host Note: Rabbit Conjugation Note: FITC Reactivity Note: Human Application Note: ELISA
  Buy from Supplier

N/A
Rabbit polyclonal antibody against Protein ERGIC-53-like conjugated to HRP Isotype Note: IgG Host Note: Rabbit Conjugation Note: HRP Reactivity Note: Human Application Note: ELISA
  Buy from Supplier

Image Search Results


S-Acylation controls the lipid environment of spike See also <xref ref-type=Figure S4 . (A) Coarse-grained (CG) model of spike’s transmembrane (TM) helix + C-terminal region (residues 1,201-end in UniProt P0DTC2 ) in trimeric form, inserted into a DPPC-(yellow)-DLiPC-(red)-cholesterol-(green) membrane model. Left, starting conditions: random lipid positions and stretched cytoplasmic tail; center, representative end state of same view after 3.75 μs of CG MD simulation of the S-palmitoylated protein depicts phase separation and spike partitioning. Right, side view of the same model after 2 μs of atomistic MD simulation in the S-palmitoylated form in a POPC membrane. (B) Quantification of contacts at equilibrium between the full TM helix, the luminal half, or the cytosolic half, and each lipid phase. Results are means ± SD (n = 10). (C) Vero E6 expressing spike-HA WT surface labeled with biotin and processed for fractionation. Western blot (WB) of biotinylated proteins (Surface-Strp. Pull-down) precipitated from each fraction were compared to unbound fractions (intracellular-unbound). (D) Quantification of spike-HA (all forms) in each fraction relative to the total signal in all 6 fractions. Results are mean ± SD, n = 3. (E and F) High-throughput automated microscopy of Vero E6 expressing spike-HA (WT, or 10C-A mutant) for 24 h immunolabeled for HA and stained with Filipin. (E) Total levels of filipin staining within HA-positive cells (or per cell—mock sample) quantified per number of nuclei. The data were averaged for 49 frames over 8 wells per condition. Each dot represents one independent well, and results are mean ± SEM. Equivalent results were obtained for three independent assays. (G) Vero E6 infected with SARS-CoV-2 24 h, MOI ≈ 0.1 were incubated with beta-methylcyclodextrin (βMCD) or not (Ctrl) for 30 min. Cell extracts were fractionated as in (C). DRM marker Caveolin1 (Cav1)-positive control, transferrin receptor (TfR)-negative control. (H and I) Quantification of spike forms (H) and caveolin 1 (I) signals as in (C). Results are mean ± SD, n = 3. (J) Vero E6 transfected with indicated siRNA (siCtrl or siMixT pool), infected and fractionated as in (G). (K–M) Quantification of (K) and (L). Spike (all forms) and (M) ERGIC53 in each fraction as in (C). Results are mean ± SD, n = 3. All p values were obtained by two-way (except for E, one-way) ANOVA. " width="100%" height="100%">

Journal: Developmental Cell

Article Title: S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity

doi: 10.1016/j.devcel.2021.09.016

Figure Lengend Snippet: S-Acylation controls the lipid environment of spike See also Figure S4 . (A) Coarse-grained (CG) model of spike’s transmembrane (TM) helix + C-terminal region (residues 1,201-end in UniProt P0DTC2 ) in trimeric form, inserted into a DPPC-(yellow)-DLiPC-(red)-cholesterol-(green) membrane model. Left, starting conditions: random lipid positions and stretched cytoplasmic tail; center, representative end state of same view after 3.75 μs of CG MD simulation of the S-palmitoylated protein depicts phase separation and spike partitioning. Right, side view of the same model after 2 μs of atomistic MD simulation in the S-palmitoylated form in a POPC membrane. (B) Quantification of contacts at equilibrium between the full TM helix, the luminal half, or the cytosolic half, and each lipid phase. Results are means ± SD (n = 10). (C) Vero E6 expressing spike-HA WT surface labeled with biotin and processed for fractionation. Western blot (WB) of biotinylated proteins (Surface-Strp. Pull-down) precipitated from each fraction were compared to unbound fractions (intracellular-unbound). (D) Quantification of spike-HA (all forms) in each fraction relative to the total signal in all 6 fractions. Results are mean ± SD, n = 3. (E and F) High-throughput automated microscopy of Vero E6 expressing spike-HA (WT, or 10C-A mutant) for 24 h immunolabeled for HA and stained with Filipin. (E) Total levels of filipin staining within HA-positive cells (or per cell—mock sample) quantified per number of nuclei. The data were averaged for 49 frames over 8 wells per condition. Each dot represents one independent well, and results are mean ± SEM. Equivalent results were obtained for three independent assays. (G) Vero E6 infected with SARS-CoV-2 24 h, MOI ≈ 0.1 were incubated with beta-methylcyclodextrin (βMCD) or not (Ctrl) for 30 min. Cell extracts were fractionated as in (C). DRM marker Caveolin1 (Cav1)-positive control, transferrin receptor (TfR)-negative control. (H and I) Quantification of spike forms (H) and caveolin 1 (I) signals as in (C). Results are mean ± SD, n = 3. (J) Vero E6 transfected with indicated siRNA (siCtrl or siMixT pool), infected and fractionated as in (G). (K–M) Quantification of (K) and (L). Spike (all forms) and (M) ERGIC53 in each fraction as in (C). Results are mean ± SD, n = 3. All p values were obtained by two-way (except for E, one-way) ANOVA.

Article Snippet: ERGIC53 , ProSci , RRID: AB_796913 Cat#PSC-PM-7213.

Techniques: Membrane, Expressing, Labeling, Fractionation, Western Blot, High Throughput Screening Assay, Microscopy, Mutagenesis, Immunolabeling, Staining, Infection, Incubation, Marker, Positive Control, Negative Control, Transfection

Spike S-acylation controls lipid organization of VLPs See also <xref ref-type=Figure S5 . (A) Untyped (Bald) or spike-HA (WT or 10C-A) pseudotyped VLPs purified from supernatants of HEK293T (see ). Normalized VLP released (mean ± SEM) was determined by quantification of Nluc-bioluminescence from 5 independent preparations. (B–D) Western blot (WB) of cell extracts and VLPs: non-typed (bald) or VLPs pseudotyped with spike-HA (WT or 10C-A mutant). GAPDH used as cellular-control. (C) Spike-HA levels in VLPs normalized against N or M and set to 1 for WT. (D) Spike cleavage in VLPs quantified as the ratio between S2 and S2 + S full length. Results are mean ± SEM, n = 3. (E) Acylrac capture assay in purified VLPs and correspondent cell extracts isolated as in (B). Total cell extracts (input, In), S-palmitoylated proteins (+NH 2 OH), and control fractions (−NH 2 OH) analyzed by WB against HA (spike). (F) WB of fractions from concentrated VLPs processed for fractionation and DRM isolation. (G and H) Quantification of (G). Spike-HA (all forms) or (H) M in each fraction divided by the total signal in the 6 fractions. Results are mean ± SD, n = 3. (I and J) Same as in (F) from lysates of VLP-producing HEK293T. Fractions were analyzed by WB and ERGIC53 levels in each fraction quantified as in (G) and (H). Results are mean ± SD, n = 3. p values were obtained by two-way ANOVA. " width="100%" height="100%">

Journal: Developmental Cell

Article Title: S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity

doi: 10.1016/j.devcel.2021.09.016

Figure Lengend Snippet: Spike S-acylation controls lipid organization of VLPs See also Figure S5 . (A) Untyped (Bald) or spike-HA (WT or 10C-A) pseudotyped VLPs purified from supernatants of HEK293T (see ). Normalized VLP released (mean ± SEM) was determined by quantification of Nluc-bioluminescence from 5 independent preparations. (B–D) Western blot (WB) of cell extracts and VLPs: non-typed (bald) or VLPs pseudotyped with spike-HA (WT or 10C-A mutant). GAPDH used as cellular-control. (C) Spike-HA levels in VLPs normalized against N or M and set to 1 for WT. (D) Spike cleavage in VLPs quantified as the ratio between S2 and S2 + S full length. Results are mean ± SEM, n = 3. (E) Acylrac capture assay in purified VLPs and correspondent cell extracts isolated as in (B). Total cell extracts (input, In), S-palmitoylated proteins (+NH 2 OH), and control fractions (−NH 2 OH) analyzed by WB against HA (spike). (F) WB of fractions from concentrated VLPs processed for fractionation and DRM isolation. (G and H) Quantification of (G). Spike-HA (all forms) or (H) M in each fraction divided by the total signal in the 6 fractions. Results are mean ± SD, n = 3. (I and J) Same as in (F) from lysates of VLP-producing HEK293T. Fractions were analyzed by WB and ERGIC53 levels in each fraction quantified as in (G) and (H). Results are mean ± SD, n = 3. p values were obtained by two-way ANOVA.

Article Snippet: ERGIC53 , ProSci , RRID: AB_796913 Cat#PSC-PM-7213.

Techniques: Purification, Western Blot, Mutagenesis, Control, Isolation, Fractionation

Journal: Developmental Cell

Article Title: S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity

doi: 10.1016/j.devcel.2021.09.016

Figure Lengend Snippet:

Article Snippet: ERGIC53 , ProSci , RRID: AB_796913 Cat#PSC-PM-7213.

Techniques: Virus, Recombinant, Amplex Red Cholesterol Assay, Luciferase, Electron Microscopy, Protease Inhibitor, Enzyme-linked Immunosorbent Assay, Neutralization, SYBR Green Assay, Lysis, Generated